PDCD1 and neoplasm: Recent advances in TNBC treatment have shifted toward immune checkpoint blockade and toward reversing reduced T cell infiltration at the tumor site by targeting the interaction between programmed cell death protein 1 (PD-1) and programmed cell death protein ligand 1 (PD-L1) [3].